Targeted antibody plus chemotherapy shows promise for Tough-to-Treat head and neck cancer
Disease control
Completed
This study tested whether adding a targeted antibody (C225, also known as cetuximab) to standard chemotherapy (cisplatin) works better than chemotherapy alone for people with advanced head and neck cancer that has spread or come back. About 120 adults with incurable squamous cell…
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated May 08, 2026 12:00 UTC